MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12882-025-04535-z

Медицинская библиотека · BMC nephrology · 2025

Adalimumab in refractory pediatric tubulointerstitial nephritis and uveitis syndrome: a case report of sustained renal-ocular remission and literature review.

Yang Danni, Xi Weibo, Liu Weiqin, Cheung Wai Wilson, Zhang Jianjiang

СтатьяКлинический случайОбзорПеревод в очереди

Аннотация

BACKGROUND

Tubulointerstitial nephritis and uveitis (TINU) syndrome is a rare disease characterized by idiopathic acute tubulointerstitial nephritis and uveitis. To date, there are no standard therapeutic protocols. The renal damage may be clinically severe and persistent, and the uveitis tends to recur or progress to a chronic state, posing significant treatment challenges. We present a pediatric case of refractory TINU syndrome successfully treated with adalimumab, which provide a reference for its management.

CASE PRESENTATION: A 7-year-old boy initially presented with mild proteinuria and acute kidney injury, accompanied by a reduced estimated glomerular filtration rate (eGFR) of 57.5 mL/min/1.73 m². A kidney biopsy revealed acute tubulointerstitial nephritis. He was treated with oral prednisolone, with partial improvement of kidney function. Three months after the first symptoms, bilateral anterior uveitis developed, establishing the diagnosis of TINU syndrome. Treatment initially involved systemic glucocorticoids combined with mycophenolate mofetil, but the uveitis persisted with recurrent episodes refractory to treatment. The patient received a 10-month course of adalimumab, a monoclonal antibody targeting Tumor necrosis factor-α (TNF-α). There was a significant resolution of ocular inflammation and normalization of kidney function, with a restored eGFR of 101.05 mL/min/1.73 m². Throughout the 1.25-year follow-up, no adverse events (including infections) occurred, and no recurrence was observed.

CONCLUSIONS

Adalimumab can effectively control inflammatory responses and reduce recurrence in pediatric TINU syndrome, with a favorable safety profile, thereby providing a novel and promising biologic alternative for steroid-resistant or refractory cases. It is recommended to focus on ocular lesions in patients with tubulointerstitial injuries to avoid missing the diagnosis of TINU syndrome.

Для цитирования: Yang Danni, Xi Weibo, Liu Weiqin, Cheung Wai Wilson, Zhang Jianjiang. Adalimumab in refractory pediatric tubulointerstitial nephritis and uveitis syndrome: a case report of sustained renal-ocular remission and literature review.. BMC nephrology. 2025. DOI: 10.1186/s12882-025-04535-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.